Appropriate use of the intrauterine device

American Family Physician

Volumn 58, Issue 9, 1998, Pages 2077-2084

  Canavan, Timothy P ^a  

^a LANCASTER GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COPPER INTRAUTERINE DEVICE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BIRTH CONTROL; CONDOM; COST EFFECTIVENESS ANALYSIS; FEMALE; FEMALE INFERTILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERMETHOD COMPARISON; INTRAUTERINE CONTRACEPTIVE DEVICE; PATIENT COUNSELING; PATIENT SELECTION; PELVIC INFLAMMATORY DISEASE;

CONTRACEPTION; FEMALE; HUMANS; INTRAUTERINE DEVICES; PATIENT EDUCATION; PATIENT SELECTION; TEACHING MATERIALS; UNITED STATES;

EID: 0032401935     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. IUDs: an update. Popul Rep B 1995;6:1-35.
2. Sivin I. Another look at the Dalkon Shield: metaanalysis underscores its problems. Contraception 1993;48:1-12 [Published erratum in Contraception 1993;48:192].
3. Christian CD. Maternal deaths associated with an intrauterine device. Am J Obstet Gynecol 1974; 119:441-4.
4. Lee NC, Rubin GL, Borucki R. The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study. Obstet Gynecol 1988;72:1-6.
5. Tatum JH, Schmidt FH, Phillips D, McCarty M, O'Leary WM. The Dalkon Shield controversy: structural and bacteriologic studies of IUD tails. JAMA 1975;231:711-7.
6. Burkman RT. Association between the intrauterine device and pelvic inflammatory disease. Obstet Gynecol 1981;57:269-76.
7. Trussell J, Leveque JA, Koenig JD, London R, Borden S, Henneberry J, et al. The economic value of contraception: a comparison of 15 methods. Am J Public Health 1995;85:494-503.
8. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor J, Trussell J. The risk of pregnancy after tubal sterilization: findings from the US Collaborative Review of Sterilization. Am J Obstet Gynecol 1996;174: 1161-70.
9. Ortiz ME, Croxatto HB, Bardin CW. Mechanisms of action of intrauterine devices. Obstet Gynecol Surv 1996;51(12 suppl):S42-51.
10. ParaGard. Package insert. Raritan, N.J.: Ortho Pharmaceutical Corp.; July 1995.
11. Pharriss BB, Erickson R, Bashaw J, Hoff S, Place VA, Zaffaroni A. Progestasert: a uterine therapeutic system for long term contraception. Philosophy and clinical efficacy. Fertil Steril 1974;25:915-21.
12. Tatum HJ, Connell EB. A decade of intrauterine contraception: 1976 to 1986. Fertil Steril 1986; 46:173-92.
13. Connell EB. Intrauterine devices. In: Kase NG, Weingold AB, Gershenson DM, eds. Principles and practice of clinical gynecology. 2d ed. New York: Churchill Livingstone, 1990:1021-42.
14. Smith MR, Soderstrom R. Salpingitis: a frequent response to intrauterine contraception. J Reprod Med 1976;16:159-62.
15. Alvarez FV, Brache V, Fernandez E, Guerrero B, Guiloff E, Hess R, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 1988;49:768-73.
16. Wilcox AJ, Weinberg CR, Armstrong EG, Canfield RE. Urinary human chorionic gonadotropin among intrauterine device users: detection with a highly specific and sensitive assay. Fertil Steril 1987;47: 265-9.
17. Intrauterine devices. JAMA 1990;263:235-6.
18. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991;78:291-8.
19. American College of Obstetricians and Gynecologists. The intrauterine device. ACOG technical bulletin no. 164. Washington, D.C.: ACOG, 1992.
20. Sivin I, Stern J. Long-acting, more effective copper T IUDs: a summary of US experience, 1970-1975. Stud Fam Plann 1979;10:263-81.
21. Sivin I, Schmidt F. Effectiveness of IUDs: a review. Contraception 1987;36:55-84.
22. White MK, Ory HW, Rooks JB, Rochat RW. Intrauterine device termination rates and the menstrual cycle day of insertion. Obstet Gynecol 1980;55:220-4.
23. Connell EB. The intrauterine device: reassessing its role as a contraceptive option. Female Patient 1996;21:33-45.
24. Foreman H, Stadel BV, Schlesselman S. Intrauterine device usage and fetal loss. Obstet Gynecol 1981;58:669-77.
25. Spornitz UM, Makabe S, Hafez ES, et al. Scanning electron microscopy of the IUD tail. Contraceptive Deliv Syst 1984;5:29-45.
26. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meink O. Intrauterine devices and pelvic inflammatory disease: an international prospective. Lancet 1992;339:785-8.
27. Sinei SK, Schulz KF, Lamptey PR, Grimes DA, Mati JK, Rosenthal SM, et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol 1990; 97:412-9.
28. Ladipo QA, Farr G, Otolorin E, Konje JC, Sturgen K, Cox P, et al. Prevention of IUD-related pelvic infection: the efficacy of prophylactic doxycycline at IUD insertion. Adv Contracept 1991;7:43-54.
29. Hatcher RA, ed. Contraceptive technology. 16th ed. New York: Irving, 1996.
30. Petitti DB, Yamamoto D, Morgenstern N. Factors associated with actinomyces-like organisms on Papanicolaou smear in users of intrauterine contraceptive devices. Am J Obstet Gynecol 1983;145: 338-41.
31. Lassise DL, Savitz DA, Hamman RF, Baron AE, Brinton LA, Levines RS. Invasive cervical cancer and intrauterine device use. Int J Epidemiol 1991;20: 865-70.
32. Cramer DW, Schiff I, Schoenbaum SC, Gibson M, Belisle S, Albrecht B, et al. Tubal infertility and the intrauterine device. N Engl J Med 1985;312:941-7.